What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

被引：19

作者：

Liu, Joyce F. ^{[1
]}

Matulonis, Ursula A. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA

来源：

CURRENT ONCOLOGY REPORTS | 2016年 / 18卷 / 05期

关键词：

Ovarian cancer; PARP inhibitors; Olaparib; Veliparib; Rucaparib; Niraparib; RECURRENT EPITHELIAL OVARIAN; OLAPARIB MAINTENANCE THERAPY; RECOMBINATION DNA-REPAIR; NEGATIVE BREAST-CANCER; HOMOLOGOUS RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; FALLOPIAN-TUBE; DOWN-REGULATION; PHASE-II; PRIMARY PERITONEAL;

D O I：

10.1007/s11912-016-0515-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly-ADP-ribose polymerase (PARP) inhibitors have been one of the most exciting developments in the treatment of ovarian cancer in recent years. Demonstration of anticancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014. Additional trials are underway or awaiting final analysis with olaparib, other PARPis, and PARPi combinations to further elucidate the activity of these drugs in various clinical settings. This review will focus on the current clinical experience and ongoing trials with PARPis in ovarian cancer.

引用

页数：9

共 50 条

[31] The Maze of PARP Inhibitors in Ovarian Cancer
Nair, Abhilasha
Chen, Alice P.
Pothuri, Bhavana
ONCOLOGY-NEW YORK, 2012, 26 (02): : 136 - +
[32] PARP inhibitors in the ovarian cancer therapy
Kruczala, Maksymilian A.
Grela-Wojewoda, Aleksandra
Cedrych, Ida
GINEKOLOGIA POLSKA, 2016, 87 (02) : 131 - 134
[33] PARP Inhibitors in Epithelial Ovarian Cancer
Taylor, Kristin N.
Eskander, Ramez N.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2018, 13 (02) : 145 - 158
[34] PARP Inhibitors in Ovarian Cancer: A Review
O'Malley, David M.
Krivak, Thomas C.
Kabil, Nashwa
Munley, Jiefen
Moore, Kathleen N.
TARGETED ONCOLOGY, 2023, 18 (04) : 471 - 503
[35] Use of PARP Inhibitors for Ovarian Cancer
Armstrong, Deborah K.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 636 - 638
[36] PARP inhibitors as single agents and in combinations for ovarian cancer: What lies ahead?
Matulonis, Ursula A.
CLINICAL CANCER RESEARCH, 2018, 24 (15) : 17 - 17
[37] PARP inhibitors in epithelial ovarian cancer: what are their potential implications for surgical management?
Peters, Inge
Marchetti, Claudia
Fagotti, Anna
Scambia, Giovanni
EJSO, 2023, 49 (09):
[38] PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
Ledermann, Jonathan A.
El-Khouly, Fatima
BRITISH JOURNAL OF CANCER, 2015, 113 : S10 - S16
[39] Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors
Lee, Elizabeth K.
Matulonis, Ursula A.
EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (02) : 165 - 188
[40] PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
Jonathan A Ledermann
Fatima El-Khouly
British Journal of Cancer, 2015, 113 : S10 - S16

← 1 2 3 4 5 →